Editor-in-Chief: Jian Ding, M.D.

Jian Ding, M.D.

Professor and Director of the Institute
Head of Division of Antitumor Pharmacology
Director of State Key Laboratory of Drug Research
Shanghai Institute of Materia Medica
Chinese Academy of Sciences
555 Zu Chong Zhi Road
Shanghai 201203, P.R. China
Tel:: 86-21-50806600-1305
Fax: 86-21-50807088
E-mail: aps@simm.ac.cn


Jian Ding, M.D. received his B.S. from Jiangxi Medical University (Jiangxi, China) and his M.D. from Kyushu University (Fukuoka, Japan). He was a postdoctoral fellow at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. Since 1994, he has been the principal investigator of the Division of Antitumor Pharmacology at the Shanghai Institute of Materia Medica. He currently serves as Editor-in-chief of Acta Pharmacologica Sinica and is on the Editorial Board of Eur J Pharmacol, J Ethnopharm and Cancer Biology & Therapy.

Areas of Focus
Anti-Tumor Pharmacology
Tumor Biology

Research Interests:

Research in the Ding lab is directed towards the following two fields: (1) Screening, research and development of new anticancer drugs including topoisomerase inhibitors, microtubule inhibitors, tumor angiogenesis inhibitors, tyrosine kinase inhibitors, heparanase inhibitors and PI3K/mTOR inhibitors; (2). Cellular and molecular mechanisms of actions of anticancer drugs, particularly DNA damage and DNA repair, signaling transduction in tumor cells, tumor multidrug resistance and tumor metastasis.

Selected papers:

1. Li WH., Shao Y., Hu LH., Zhang XW., Chen Y., Tong LJ., Li C., Shen X., Ding J*. BM6, a new semi-synthetic Vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles. Cancer Biol Ther 2007 (in press).

2. Tian F, Zhu CH, Zhang XW, Xie X, Xin XL, Yi YH, Lin LP, Geng MY, Ding J*. Philinopside E, a New Sulfated Saponin from Sea Cucumber, Blocks the Interaction between KDR and {alpha}v{beta}3 Integrin via Binding to the Extracellular Domain of KDR. Mol Pharmacol. 2007 (in press)

3. Huang M., Gao HY., Chen Y., Zhu H., Cai YJ., Zhang XW., Miao ZH., Jiang HL., Shen HW., Lin LP., Lu W., Ding J*. Chimmitecan, a Novel 9-Substituted Camptothecin, with Excellent Improvement in Anti-cancer Pharmacological Profiles both In Vitro and In Vivo. Clin Cancer Res 13:1298-1307, 2007

4. Zhu H., Huang M., Yang F., Chen Y., Miao ZH., Qian XH., Xu YF., Qin YX., Luo HB., Shen X., Geng MY., Cai YJ., Ding J*. R16, a novel amonafide analogue, induces apoptosis and G2/M arrest via poisoning topoisomerase II. Mol Cancer Ther 6:484-95, 2007.

5. Ding J*., Miao ZH., Meng LH. Emerging cancer therapeutic opportunities target DNA repair systems. Trends in Pharmacol Sci. 27: 338-344,2006.

6. Zhang C., Yang F., Zhang* XW., Wang SC, Li MH, Lin LP, Ding J*. Grateloupia longifolia polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC-1 endothelial cells. British J Pharmacol 148: 741-751,2006.

7. Tong YG., Zhang XW., Geng MY., Yue JM., Xin XL., Tian F., Shen X., Tong LJ., Li MH., Zhang C., Li WH., Lin LP., Ding J*. Pseudolarix acid B, a novel tubulin-binding agent, inhibits angiogenesis by interacting with a distinct binding site on tubulin. Mol Pharmacol 69: 1226-1233, 2006.

8. Wang XN, Yin S, Fan CQ, Wang FD, Lin LP, Ding J*, Yue JM. Turrapubesins A and B, first examples of halogenated and maleimide-bearing limonoids in nature from Turraea pubescens. Org Lett. 2006; 8:3845-8.

9. Yin S, Fan CQ, Wang XN, Lin LP, Ding J, Yue JM. Xylogranatins A-D: novel tetranortriterpenoids with an unusual 9,10-seco scaffold from marine mangrove Xylocarpus granatum. Org Lett. 2006; 8:4935-8.

10. Gan LS., Fan CQ., Yang SP., Wu Y., Lin LP., Ding J., Yue JM. Flueggenines A and B, two novel C,C-linked dimeric indolizidine alkaloids from Flueggea virosa. Org Lett 8: 2285-2288, 2006.

11. Zhong L., Guo XN., Zhang XH., Sun QM., Tong LJ., Wu ZX., Luo XM., Jiang HL., Nan FJ., Zhang XW., Lin LM., Ding J*. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFR. Cancer Biol Ther 5: 323-330, 2006.

12. Yang F., Chen Y., Duan WH., Zhang C., Zhu H., Ding J*. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 119: 1184-1193, 2006.

13. Gao Y., Lin LM., Hou YT., Zhu CH., Nan FJ., Zhang XW., Chen Y., Ding J*. Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther 5: 978-985, 2006.

14. Wang J., Ou ZL., Hou YF., Luo JM., Shen ZZ., Ding J*., Shao ZM*. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25: 7201-7211, 2006.

15. Zhao HJ., Liu HY., Chen Y., Xin XL., Li J., Hou YT., Zhang XW., Geng MY., Ding J*. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting bFGF, combats tumor angiogenesis and metastasis. Cancer Res 66: 8779-8787, 2006.

16. Hu CX., Zuo ZL., Xiong B., Ma JG., Geng MY., Lin LP., Jiang HL., Ding J*. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 70: 1593-1601, 2006.

17. Lu HR., Meng LH., Huang M., Zhu H., Miao ZH., Ding J*. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells. Cancer Chemoth Pharmacol 55: 286-294, 2005.

18. Tong YG., Zhang XW., Tian F., Yi YH., Xu QZ., Li L., Tong LJ., Lin LP., Ding J*. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer 114: 843-853, 2005.

19. Liu HY., Geng MY*., Xin XL., Li FC., Zhang ZQ., Li J., Ding J*. Multiple and multivalent interactions of novel anti-AIDS drug candidate sulfated polymannuronate (SPMG)-derived oligosaccharides with gp120 and their anti-HIV activities. Glycobiology 15: 501-510, 2005.

20. Miao BC., Li J., Fu XY., Ding J*., Geng MY*. T-cell receptor (TCR)/CD3 is involved in sulphated polymannuroguluronate (SPMG)-induced T lymphocyte activation. Inter Immunopharmacol 5: 1171-1182, 2005.

21. Lang JY., Chen H., Zhou J., Zhang YX., Zhang XW., Li MH., Lin LP., Zhang JS., Waalkes MP., Ding J*. Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res 11: 3455-3464, 2005.

22. Chen Y., Zhang YX., Li MH., Zhao WM., Shi YH., Miao ZH., Zhang XW., Lin LP., Ding J*. Antiangiogenic activity of 11,11’-dideoxyverticillin, a natural product isolated from the fungus Shiraia Bambusicola. Biochem Biophys Res Comm 329: 1334-1342, 2005.

23. Chen Y., Miao ZH., Zhao WM., Ding J*. The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11’-dideoxyverticillin-induced G2/M arrest. FEBS Lett 579: 3683-3690, 2005.

24. Lu HR., Zhu H., Huang M., Chen Y., Cai YJ., Miao ZH., Ding J*. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 68: 983-994,2005.

25. Tian F., Zhang XW., Tong YG., Yi YH., Zhang SL., Li L., Sun P., Lin LP., Ding J*. PE, a new sulphated saponin from sea cucumber, exhibits anti-angiogetic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther 4: 874-882, 2005.

26. Guo XN., Zhong L., Tan JZ., Li J., Luo XM., Jiang HL., Nan FJ., Lin LM., Zhang XW., Ding J*. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biol Ther 4: 1125-1132, 2005.

27. Miao ZH., Tang LJ., Zhang JS., Han JX., Ding J*. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. Int J Cancer 110: 627-632, 2004.

28. Hou YF., Yuan ST., Li HC., Wu J., Lu JS., Liu G., Shen ZZ., Ding J*., Shao ZM*. ERß exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23: 5799-5806, 2004.

29. Miao BC., Geng MY*.,, Li J., Li FC., Chen HX., Guan HS., Ding J*. Noval anti-AIDS drug candidate polymannuroguluronate (SPMG) specifically targeting CD4 receptor on lymphocytes. Biochem Pharmacol. 68: 641-649, 2004.

30. Liu WJ., Zhang YW., Shen Y., Jiang JF., Miao ZH., Ding J*. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells. Biochem Biophys Res Comm 323: 660-667, 2004.

31. Li MH., Miao ZH., Tan WF., Yue JM., Zhang C., Lin LP., Zhang XW., Ding J*. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1a by promoting proteasome-mediated degradation. Clin Cancer Res 10: 8266-8274, 2004.

32. Miao ZH, Ding J*. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res. 2003; 63 (15): 4527-4532.

33. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J*. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer. 2003; 106(1):108-15.